Drugs / trifluridine-tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04489173 | Sep 2020 → Jan 2024 | breast cancer, chemotherapy-induced toxicity | Dutch Breast Cancer Research Group | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trifluridine-tipiracil | “Trifluridine-tipiracil has shown survival benefit in heavily pre-treated patients with metastatic colorectal and in gastric cancer refractory to a fluoropyrimidine.” PMID 40017682 ↗ Jan 2025 |
| Route | Oral | “Trifluridine/tipiracil will be administered orally BID” NCT04489173 ↗ |